ABP-7
Also known as Actin Binding Peptide-7, TB-500 Fragment, Ac-LKKTETQ, Thymosin Beta-4 (17-23) fragment
An N-acetylated heptapeptide fragment of Thymosin Beta-4 (the LKKTETQ actin-binding domain) sold for research into actin regulation and wound repair.
Typical use cases
Dosing guidelines
Titration
Typically flat-dosed in the limited literature; no validated titration scheme.
Reconstitution
10 mg vial: ~2 mL bacteriostatic water yields ~5 mg/mL.
Injection sites
Subcutaneous in research handling (e.g. abdomen), by analogy to TB-500/peptide practice.
Storage & handling
Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).
Side effects
- Unknown human safety profile (no clinical data)
- Injection-site reaction (by analogy to peptide injectables)
Research summary
ABP-7 corresponds to the acetylated 17–23 (LKKTETQ) actin-binding sequence of Thymosin Beta-4, and is hypothesized to sequester G-actin and limit its polymerization into F-actin, thereby influencing cell migration and tissue-repair pathways. Note that the available description comes largely from vendor material: there is no peer-reviewed literature on the isolated 'ABP-7' entity itself, and the mechanism/benefit claims are extrapolated from the parent Thymosin Beta-4 protein. There are no human pharmacokinetic or safety data, and it is sold strictly as a research chemical. Educational only — not medical advice.
Key references
- Goldstein, Hannappel & Kleinman, Trends Mol. Med. (2005) — Thymosin β4 actin-sequestering protein and tissue repair
- Sosne et al., Exp. Eye Res. (2010) — Thymosin β4 active fragment(s) and corneal wound healing
Related compounds
Where to buy
These are affiliate links. Purchasing through them helps support DoseForge at no extra cost to you.
Educational reference only — not medical advice. Dosing figures are commonly-cited ranges, not prescriptions. Consult a qualified clinician.
Log doses, rotate sites, watch your progress — free.